Performance comparison of the Cobas® Liat® and Cepheid® GeneXpert® systems on SARS-CoV-2 detection in nasopharyngeal swab and posterior oropharyngeal saliva
| Autor: | Lawrence W. C. Chan, Sze Chuen Cesar Wong, William C. Cho, Wai Ming Stanley Leung, Hin Fung Tsang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
COVID-19 diagnosis Saliva viruses Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Point-of-care testing Oropharynx Real-Time Polymerase Chain Reaction Sensitivity and Specificity POCT Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine Nasopharynx Genetics Humans Medicine Nucleic Acid Amplification Tests skin and connective tissue diseases Molecular Biology Original Research GeneXpert MTB/RIF business.industry fungi virus diseases Gold standard (test) SARS-CoV-2 PCR Virology body regions 030104 developmental biology Real-time polymerase chain reaction COVID-19 Nucleic Acid Testing 030220 oncology & carcinogenesis Performance comparison Coronavirus disease-2019 Molecular Medicine business Research Article severe acute respiratory syndrome coronavirus 2 |
| Zdroj: | Expert Review of Molecular Diagnostics article-version (VoR) Version of Record |
| ISSN: | 1744-8352 1473-7159 |
| Popis: | Background: Nucleic acid amplification tests (NAATs) based methods such as real-time reverse transcription polymerase-chain reaction (real-time RT-PCR) are the gold standard for diagnosis of current infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The cobas® Liat® and cepheid® GeneXpert® systems are two rapid real-time RT-PCR platforms offering rapid, specimen-to-answer detection of SARS-CoV-2. Research design and methods: In this study, we compared the performance of these two systems on SARS-CoV-2 detection in 9 nasopharyngeal swab (NPS) and 70 posterior oropharyngeal saliva specimens collected from 79 patients suspected of SARS-CoV-2 infection between August 2020 and March 2021. Results: The Positive Percent Agreement (PPA), Negative Percent Agreement (NPA) and overall Percent Agreement (OPA) between cepheid® Xpress SARS-CoV-2 assay and cobas® Liat® SARS-CoV-2 & Influenza A/B assay were found to be 100%. We demonstrated an excellent overall test concordance of the Liat® SARS-CoV-2 & Influenza A/B assay and Xpress SARS-CoV-2 assay. The small sample size of SARS-CoV-2 positive and weak-positive specimens is the inherent limitation of this study. Conclusions: The performance of the cobas® Liat® SARS-CoV-2 & Influenza A/B assay is equivalent to the cepheid® Xpress SARS-CoV-2 assay for SARS-CoV-2 detection using NPS and posterior oropharyngeal saliva. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|